2024-09-08 - Analysis Report
##  ABBV Stock Analysis Report

**Company Overview:** AbbVie Inc. (ABBV) is a research-based global biopharmaceutical company developing and marketing advanced therapies for various diseases. 

**Performance Analysis:**

**1. Outperformance vs. S&P 500:**

* **Cumulative Return (ABBV):** 102.68%
* **Cumulative Return (VOO):** 81.34%
* **Difference:** 21.34%
* **Relative Outperformance:** 70.77% (Based on historical data, ABBV's current outperformance is at the 70.77th percentile compared to its past performance against VOO).

**2. Recent Price Trends:**

* **Closing Price:** $193.4
* **5-Day Moving Average:** $195.45
* **20-Day Moving Average:** $194.82
* **60-Day Moving Average:** $181.23

**3. Technical Indicators:**

* **RSI:** 48.4 (Neutral)
* **PPO:** -0.56 (Slight Bearish)
* **Delta_Previous_Relative_Divergence:** -0.26 (Short-term downward trend)
* **Expected Return:** 13.81% (Potential 5-year expected return on investment)

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Expected EPS |
|-------------|-------|--------------|
| 2024-07-25 | 2.65  | 2.57         |
| 2024-04-26 | 2.31  | 2.26         |
| 2024-02-02 | 2.79  | 2.76         |
| 2023-10-27 | 2.95  | 2.86         |
| 2023-07-27 | 2.91  | 2.79         |

**Analysis:** 

ABBV has consistently exceeded earnings estimates in recent quarters, demonstrating strong profitability. The company's recent earnings of 2.65 for the quarter ending 2024-07-25 surpassed the expected EPS of 2.57. 

**Overall Summary:**

ABBV has outperformed the S&P 500 in the long term, with a current outperformance at the 70.77th percentile historically.  While recent technical indicators suggest a slight bearish trend, ABBV's consistent earnings beats and strong expected return make it a potentially attractive investment. 
